Status:
NOT_YET_RECRUITING
Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
In the immediate postoperative period following cardiac surgery, many patients require short-term sedation until cardiovascular and respiratory stability has been achieved and weaning from artificial ...
Eligibility Criteria
Inclusion
- Sign the informed consent form voluntarily and follow the plan requirements;
- age over 60 years old;
- post coronary artery bypass surgery;
- anticipated mechanical ventilation duration \>8 hours
- admission to the cardiac surgery intensive care unit of Zhongshan hospital, Fudan University
Exclusion
- delirium before surgery
- severe cognitive dysfunction before surgery
- patients with over degree II A-V block or consistent bradycardia
- patients who are still not awake 12 hours after surgery
- patients who are agitated or cannot follow command
- patients with mechanical circulatory support (ECMO, IABP)
- patients who are allergy to propofol or remimazolam
- BMI≥30kg/m2
- patients with much drainage, the surgery ask for blood pressure control or reopen the chest
Key Trial Info
Start Date :
July 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
338 Patients enrolled
Trial Details
Trial ID
NCT06496165
Start Date
July 15 2024
End Date
December 31 2026
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital Fudan university
Shanghai, Shanghai Municipality, China, 200032